Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly and | Svizzera | Salute | Prodotti farmaceutici | 739,21 Mrd CHF | 77x | 0,72 | 790 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Roche Holding | Svizzera | Salute | Prodotti farmaceutici | 250,87 Mrd CHF | 28,7x | -1,03 | 316,20 CHF | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 14,3% Rialzo | Fai l’upgrade a Pro+ | |
Roche Holding Participation | Svizzera | Salute | Prodotti farmaceutici | 237,19 Mrd CHF | 30,3x | -1,03 | 299,20 CHF | 0,3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 0,1% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | Svizzera | Salute | Prodotti farmaceutici | 193,18 Mrd CHF | 18,3x | -1,04 | 97,66 CHF | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7% Rialzo | Fai l’upgrade a Pro+ | |
Novartis | Svizzera | Salute | Prodotti farmaceutici | 193,18 Mrd CHF | 18,3x | -1,04 | 98,06 CHF | 0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Sandoz | Svizzera | Salute | Prodotti farmaceutici | 17,42 Mrd CHF | -2.379,2x | 25,2 | 39,55 CHF | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 7,4% Rialzo | Fai l’upgrade a Pro+ | |
Siegfried Holding Ltd | Svizzera | Salute | Prodotti farmaceutici | 4,20 Mrd CHF | 25,8x | 0,67 | 961 CHF | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 18,8% Rialzo | Fai l’upgrade a Pro+ | |
Galenica Sante | Svizzera | Salute | Prodotti farmaceutici | 4,02 Mrd CHF | 22,7x | -0,71 | 80,70 CHF | 0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | -3% Ribasso | Fai l’upgrade a Pro+ | |
Dottikon Es Holding AG | Svizzera | Salute | Prodotti farmaceutici | 2,79 Mrd CHF | 37,2x | -3,13 | 201,50 CHF | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Joincare Pharmaceutical DRC | Svizzera | Salute | Prodotti farmaceutici | 2,63 Mrd CHF | 14,7x | 4,95 | 7,18 CHF | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
COSMO Pharma | Svizzera | Salute | Prodotti farmaceutici | 1,05 Mrd CHF | 16,1x | 0,03 | 65,70 CHF | 0,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 37,6% Rialzo | Fai l’upgrade a Pro+ | |
PolyPeptide Group AG | Svizzera | Salute | Prodotti farmaceutici | 687,71 Mln CHF | -31,4x | -1,3 | 20,60 CHF | -1,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Santhera Pharmaceuticals Holding | Svizzera | Salute | Prodotti farmaceutici | 207,82 Mln CHF | 2,8x | 0,02 | 16,26 CHF | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Curatis Holding | Svizzera | Salute | Prodotti farmaceutici | 53,67 Mln CHF | -0,1x | 11,40 CHF | 6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Spexis | Svizzera | Salute | Prodotti farmaceutici | 4,06 Mln CHF | -0,2x | 0,010 CHF | -87,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |